# PW MEDTECH GROUP LIMITED
# 普华和顺集团公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1358)**

## VOLUNTARY ANNOUNCEMENT
## PROGRESS ON THE SUBSEQUENT LISTING OF SICHUAN RUIJIAN MEDICAL ON BEIJING STOCK EXCHANGE

This announcement is made by PW Medtech Group Limited (the "**Company**") on a voluntary basis.

Reference is made to (i) the relevant announcements of the Company dated May 20, 2024, July 2, 2024, October 2, 2024, December 5, 2024, December 9, 2024, March 25, 2025, June 20, 2025 and August 11, 2025; (ii) the circular of the Company dated January 21, 2025 (the "**Circular**"); and (iii) the overseas regulatory announcement of the Company dated April 30, 2025, in relation to, among others, the possible major transaction and deemed disposal in relation to the proposed listing of Sichuan Ruijian Medical. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular. As disclosed in the Circular, the NEEQS Quotation was approved by the NEEQ Co., Ltd. and was successfully completed. Further, as disclosed in the relevant announcement of the Company dated March 25, 2025, Sichuan Ruijian Medical has submitted its application for the Subsequent Listing to the Beijing Stock Exchange on the same day. The Board hereby provides the latest update on the Subsequent Listing to its Shareholders.

As the cut-off date of the financial statements of Sichuan Ruijian Medical contained in its application documents is December 31, 2024 and the effective period of which will expire soon, on September 26, 2025, Sichuan Ruijian Medical submitted an application to the Beijing Stock Exchange voluntarily for the suspension of the Subsequent Listing's review process. As at the date of this announcement, the review status of the Subsequent Listing has been adjusted by the Beijing Stock Exchange to suspension of review accordingly. On September 30, 2025, Sichuan Ruijian Medical received the "Second Review Inquiry Letter on Sichuan Ruijian Medical Technology Co. Ltd.'s Application for Public Stock Issuance and Listing on the Beijing Stock Exchange" issued by the Beijing Stock Exchange. For the avoidance of doubt, neither the Subsequent Listing nor its review process has been terminated, and as the matters related to the Subsequent Listing are still ongoing, the shares of Sichuan Ruijian Medical shall remain suspended from trading on the NEEQs. Further announcement(s) will be made by the Company in accordance with the Listing Rules as and when appropriate.

**Shareholders and potential investors should note that the Subsequent Listing is subject to, among other things, the prevailing market conditions and approvals from relevant authorities, including the CSRC and the Beijing Stock Exchange. Accordingly, Shareholders and potential investors should be aware that the Company does not guarantee that the Subsequent Listing will materialize, nor the timing thereof. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board
**PW Medtech Group Limited**
**Yue'e Zhang**
*Chairman & Chief Executive Officer*

Hong Kong, September 30, 2025

*As at the date of this announcement, the Board comprises one executive director, namely, Ms. Yue'e Zhang; two non-executive directors, namely Mr. Jiang Liwei and Mr. Lin Junshan; and three independent non-executive directors, namely, Mr. Wang Xiaogang, Mr. Chen Geng and Ms. Wang Fengli.*